Drugs / Avadomide
Avadomide
also known as
CC-122 · Avadomida · AVADOMIDE HYDROCHLORIDE · CC-122 HCI · CC-122 HCl · CC-122 HYDROCHLORIDE
Other / unclassified targets CRBN
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT05688475 | Apr 2023 → Oct 2026 expected | non-Hodgkin lymphoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03340662 | Nov 2017 → Jan 2018 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03283202 | Oct 2017 → Jul 2019 | diffuse large B-cell lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03097016 | Mar → Dec 2017 | impaired renal function disease | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02509039 | Sep 2015 → May 2023 | non-Hodgkin lymphoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02417285 | May 2015 → May 2019 | diffuse large B-cell lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02323906 | Jan 2015 → Dec 2016 | hepatocellular carcinoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02234999 | Sep → Oct 2014 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02049528 | Jan → Feb 2014 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02031419 | Dec 2013 → Dec 2023 | diffuse large B-cell lymphoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT01421524 | Sep 2011 → Nov 2023 | diffuse large B-cell lymphoma, glioblastoma, plasma cell myeloma, primary central nervous system lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03310619 | Dec 2017 → Feb 2023 | diffuse large B-cell lymphoma, follicular lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02859324 | Sep 2016 → Mar 2020 | hepatocellular carcinoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02406742 | Jul 2015 → Jul 2020 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03834623 | May 2019 → Jun 2021 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avadomide | “Avadomide (CC-122) is a novel oral cereblon-modulating agent with promising activity in non-Hodgkin lymphoma.” PMID 32758434 ↗ Aug 20202“Avadomide (CC-122) is a cereblon-modulating agent with immunomodulatory and direct antitumor activities.” PMID 31977002 ↗ Mar 2020 |
| Known as | Avadomida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989934 ↗ |
| Known as | AVADOMIDE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989934 ↗ |
| Known as | CC-122 | “Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration” NCT03283202 ↗14“Avadomide (CC-122) is a novel oral cereblon-modulating agent with promising activity in non-Hodgkin lymphoma.” PMID 32758434 ↗ Aug 2020 |
| Known as | CC-122 HCI | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989934 ↗ |
| Known as | CC-122 HCl | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989934 ↗ |
| Known as | CC-122 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989934 ↗ |
| Modality | Other / unclassified | “a new class of experimental drug (Pleiotropic Pathway Modulator)” NCT01421524 ↗ |
| Route | Oral | “Pleiotropic Pathway Modifier CC-122 Administered Orally” NCT01421524 ↗ |
| Target | CRBN | “Avadomide (CC-122) is a novel oral cereblon-modulating agent with promising activity in non-Hodgkin lymphoma.” PMID 32758434 ↗ Aug 2020 |